Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
This study has been completed.
Sponsor:
Actelion
ClinicalTrials.gov Identifier:
NCT00086463
First Posted: July 5, 2004
Last Update Posted: April 1, 2011
Information provided by:
Actelion
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
| Condition | Intervention | Phase |
|---|---|---|
| Pulmonary Arterial Hypertension Ayerza Syndrome Pulmonary Hypertension | Drug: Iloprost or placebo | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double Primary Purpose: Treatment |
| Official Title: | A Safety and Pilot Efficacy Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With PAH |
Resource links provided by NLM:
Further study details as provided by Actelion:
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2004 |
| Study Completion Date: | January 2006 |
| Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
This is a randomized, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) with an NYHA Class of III or IV who are receiving conventional therapy and bosentan. Subjects who fulfill the inclusion and exclusion criteria will be randomized to study drug (active or placebo) at a frequency of 6-9 inhalations per day for 12 weeks and will continue conventional therapy and bosentan. At the end of the double-blind phase study, open label Iloprost will be provided.
Eligibility
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 75 Years (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of PAH due to PPH, connective tissue disease, HIV, or repaired (≥ 1 year) ASD, VSD, or PDA
- NYHA Functional Class III or IV
- On bosentan for at least 16 weeks, with the dose stable (maximum dose 125 mg BID) for at least 8 weeks
- Age 12-75 years, of either gender
- Six minute walk distance 100-425 meters at Baseline
Exclusion Criteria:
- Any new long-term treatment for PAH added within the last 4 weeks
- Any therapy with a PDE (phosphodiesterase), L -arginine or a prostaglandin, concurrently, or within the last 4 weeks
- PAH related to chronic thromboembolic disease, portopulmonary disease, or any etiology other than PPH, connective tissue disease, HIV, or repaired ASD, VSD, or PDA
Contacts and Locations
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00086463
Locations
| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35294 | |
| United States, California | |
| UCSD Medical Center | |
| La Jolla, California, United States, 92037 | |
| Stanford University Medical Center | |
| Palo Alto, California, United States, 94305 | |
| UCSF Medical Center | |
| San Francisco, California, United States, 94143 | |
| Harbor-UCLA Medical Center | |
| Torrance, California, United States, 90502 | |
| United States, Colorado | |
| The Children's Hospital | |
| Denver, Colorado, United States, 80218 | |
| University of Colorado HSC | |
| Denver, Colorado, United States, 80262 | |
| United States, Illinois | |
| Rush Heart Institute, Center for Pulmonary Heart Disease | |
| Chicago, Illinois, United States, 60612 | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21205 | |
| United States, Michigan | |
| University of Michigan | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States, 55095 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Pennsylvania | |
| University of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
| United States, Texas | |
| Baylor College of Medicine | |
| Houston, Texas, United States, 77030 | |
| United States, Utah | |
| Latter Day Saints Hospital | |
| Salt Lake City, Utah, United States, 84143 | |
Sponsors and Collaborators
Actelion
Investigators
| Study Director: | Henry Hsu, M.D. | CoTherix |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00086463 History of Changes |
| Other Study ID Numbers: |
STEP STUDY STEP Pulmonary Hypertension Pulmonary Artery Cotherix |
| First Submitted: | July 1, 2004 |
| First Posted: | July 5, 2004 |
| Last Update Posted: | April 1, 2011 |
| Last Verified: | March 2011 |
Keywords provided by Actelion:
|
STEP PAH iloprost inhalation prostacyclin |
Additional relevant MeSH terms:
|
Hypertension Hypertension, Pulmonary Familial Primary Pulmonary Hypertension Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |
Bosentan Iloprost Antihypertensive Agents Endothelin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Vasodilator Agents |